サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751231

鉄剤の静脈注射市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント予測、2025年～2030年

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
鉄剤の静脈注射市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月21日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

鉄剤の静脈注射市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の鉄剤の静脈注射市場規模は2025年から2030年にかけてCAGR 9.1%で拡大し、2030年には56億2,000万米ドルに達する見込みです。

予測期間中、業界の競争はより高いレベルで維持されると予想されます。同市場は、収益シェアの大半を世界企業が占めています。さらに、成長機会が新たなプレイヤーを引き付け、競争企業間の敵対関係をさらに強化しています。市場は断片化されており、主要企業はより大きなシェアを獲得するために、戦略的提携、買収、新薬の上市など、広範な成長戦略を採用しています。

感染症による高い疾病負担は、栄養不良と相まって、この地域の小児の貧血の主な原因の一つとなっています。新型コロナウイルスの大流行も、重症患者の貧血を増加させ、場合によっては低酸素症を引き起こしています。このため、世界中で貧血治療用の鉄剤の需要がさらに高まっています。

貧血の有病率の増加は、様々な婦人科疾患や消化器疾患にも起因しており、静脈内治療の世界の普及を促進しています。例えば、貧血の全体的な有病率は、非妊娠女性で29.6%、同年齢層の妊娠女性で36.5%です。ヘルスケア予算の増加と投資の増加により、市場は予測期間中に大きく成長すると予想されます。

経口鉄剤の欠点である胃痛、便秘、食欲不振、吐き気、嘔吐などの消化器系の問題は、患者が静脈注射剤を好む理由となっています。鉄剤の静脈注射を行うことで、体内への鉄の取り込みが促進され、赤血球造血刺激因子（ESA）の働きが促進され、貧血状態が改善することが示されています。その他の利点としては、心臓の健康が保たれること、透析患者、特に血液透析を受けている患者が使用できることなどが挙げられます。

鉄剤の静脈内投与市場レポートハイライト

  • カルボキシマルトース鉄は、その用途の増加、副作用の少なさと相まって優れた性能、コストの削減により、2024年には鉄剤の静脈注射業界を支配しました。
  • スクロース鉄は2024年に市場で大きなシェアを占めました。重篤なアレルギー反応の発生率が低いことが、これらの薬剤の採用率を高めています。
  • CKDとCKDに関連した鉄欠乏性貧血患者の増加により、慢性腎臓病セグメントが2024年に最大のシェアを占めました。
  • 北米は、点滴薬の高い需要と消化器疾患、がん、CKDの有病率の増加により、2024年に最大の地域シェアを占めました。
  • アジア太平洋地域は、アンメットニーズの高まり、医療費の増加、既存世界企業の現地プレゼンスにより、推定・予測期間中に最も急成長します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 鉄剤の静脈注射市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 鉄剤の静脈注射市場：製品別 ビジネス分析

  • 製品別市場シェア、2024年と2030年
  • 製品別セグメントダッシュボード
  • 市場規模、予測、動向分析（製品別、2018～2030年）
  • 鉄デキストラン
  • 鉄スクロース
  • カルボキシマルトース第二鉄
  • その他

第5章 鉄剤の静脈注射市場：用途別 ビジネス分析

  • 用途別市場シェア、2024年および2030年
  • 用途別セグメントダッシュボード
  • 市場規模、予測、動向分析（用途別、2018～2030年）
  • 慢性腎臓病
  • 炎症性腸疾患
  • がん
  • その他の病気

第6章 鉄剤の静脈注射市場：地域別 推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年
  • 北米
    • 国別、2018年～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • AbbVie Inc.
    • AMAG Pharmaceuticals（Covis Pharma）
    • Daiichi Sankyo Company, Ltd.
    • Sanofi
    • Vifor Pharma Management Ltd.（CSL）
    • PHARMACOSMOS A/S
    • Zydus Group
    • Rockwell Medical, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global intravenous iron drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 40 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 42 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 46 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 47 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 49 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 63 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Intravenous iron drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Intravenous iron drugs market dynamics
  • Fig. 12 Intravenous iron drugs market: Porter's five forces analysis
  • Fig. 13 Intravenous iron drugs market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Iron Dextran market, 2018 - 2030 (USD Million)
  • Fig. 16 Iron Sucrose market, 2018 - 2030 (USD Million)
  • Fig. 17 Ferric Carboxymaltose market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Application market, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic kidney disease market, 2018 - 2030 (USD Million)
  • Fig. 21 Inflammatory bowel disease market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Other Diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Intravenous iron drugs market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework
目次
Product Code: GVR-4-68038-000-2

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Iron Dextran
    • 4.4.1. Iron Dextran Market, 2018 - 2030 (USD Million)
  • 4.5. Iron Sucrose
    • 4.5.1. Iron Sucrose Market, 2018 - 2030 (USD Million)
  • 4.6. Ferric Carboxymaltose
    • 4.6.1. Ferric Carboxymaltose Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Chronic Kidney Disease
    • 5.4.1. Chronic Kidney Diseases Market, 2018 - 2030 (USD Million)
  • 5.5. Inflammatory Bowel Disease
    • 5.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Other Diseases
    • 5.7.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AMAG Pharmaceuticals (Covis Pharma)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Daiichi Sankyo Company, Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Vifor Pharma Management Ltd. (CSL)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. PHARMACOSMOS A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Zydus Group
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Rockwell Medical, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives